strategy that targets the homeostatic pathways and reward pathways associated with food intake.
Neurophysiologic Regulation of Obesity
Control over food intake is essential for weight management and represents an important aim of anti-obesity therapy. The homeostatic mechanisms responsible for energy intake and expenditure are largely regulated by the central nervous system, which integrates signals from the gastrointestinal system, adipose tissue, liver, muscle, and pancreas. This information, together with a number of higher brain centers, regulates weight. 17 A major regulatory region of the brain involved in body weight homeostasis is the hypothalamus. When humans feed, peripheral signals are sent to the hypothalamus to stop eating for several hours.
These signals act on a number of neurons, including the anorexigenic pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. Stimulation of POMC neurons results in increased release of several hormones including a-melanocyte-stimulating hormone (a-MSH), which signals the brain to stop eating and increase energy expenditure. 18 Interestingly, b-endorphin is co-secreted with a-MSH from POMC 17 and provides an autoinhibitory feedback mechanism to inhibit further POMC activation. In other words, at the same time that the central control part of the brain is telling the body to stop eating and increase energy expenditure, it is also ensuring that this message is transient, in order that the body does not stop eating for too long and returns to conserving energy (presumably an adaptive survival response). The combination of these actions in part regulates energy balance, and this regulation can be altered with weight change. 17, 19 This is an example of the complex physiologic mechanisms regulating food intake and may explain why single drugs with single mechanisms of action within a pharmacologic treatment may in some cases not provide as much weight loss as combination treatment approaches that combine multiple mechanisms of action.
The caloric and nutritional values of food are not the only factors affecting food intake; food is associated with intrinsic reward value and the hedonic and emotional aspects of eating are of increasing importance in our obesigenic environment. It is now known that the hedonic control of food intake can override metabolic and homeostatic signals of satiety, 20, 21 which can result in overconsumption. Excessive food consumption will take place with food cravings and a loss of control over food intake despite awareness of its negative consequences. 22 The availability of highly palatable and rewarding (i.e. fat, sweet) food can significantly affect homeostatic balance, resulting in dysregulated food intake. The behavioral aspects of eating and obesity are currently the subjects of active clinical research.
An important regulator of hedonic eating behavior is the mesolimbic dopamine system, or reward system. The ventral tegmental area, a group of neurons located in the midbrain, is the origin of mesolimbic dopamine pathways. These release dopamine, which affects a number of brain regions including the ventral striatum, nucleus accumbens, prefrontal cortex, and amygdala. 23, 24 Dopamine signaling is implicated in the 'wanting' or desire of certain foods, which underlie food craving. 23 The pleasurable feeling ('liking') associated with rewarding stimuli is governed by opioid signaling. 25, 26 Opioid compounds, particularly those selective for the m-opioid receptor within the nucleus accumbens and surrounding ventral striatum, induce a potent increase in food intake. 27 Opiate stimulation of orexin signaling in the ventral tegmental area has been associated with increased consumption of palatable foods. 28 Brain regions known to be responsible for addiction have been associated with eating behavior. The amygdala is linked to the olfactory signaling system and can influence appetite. The complex interplay of these factors is illustrated in Figure 1 . 21, 29, 30 Genetic variability in the neurophysiology of the reward system may explain why some individuals are more susceptible than others to weight gain. 31, 32 Obese individuals are known to demonstrate different neural responses in response to food cues, [33] [34] [35] [36] including impairments in dopaminergic pathways. 37 Visual stimulation with food cues activates regions related to reward anticipation and habit learning in the dorsal striatum. It has been shown that individuals who are obese will have an increased activation of these regions in the brain to highcalorie food images. This results in BMI-dependent activation in regions related to taste, motivation, emotion, and memory, and this activation is independent of levels of hunger and satiation. [38] [39] [40] Differences in these neural regions in obese individuals have been associated with higher levels of food craving and dysregulated eating behaviors, 37, 41 and may influence food choice and consumption. 42 These changes may also underlie delayed satiation, reduced perception of caloric intake and increase in hunger in obese individuals following a 10 % weight loss. Therefore, treatments that affect neural responses to food and food-seeking motivations such as craving may represent a novel approach in designing interventions to treat obesity. 
Sustained-release Naltrexone/Bupropion-A Novel Pharmacologic Approach to the Treatment of Food Craving and Obesity

History of Use and Mechanism of Action
Combination therapies are an attractive option for pathologic states resulting from multiple regulatory mechanisms. The combination of naltrexone and bupropion (NB) in a sustained-release formulation is a novel therapeutic approach to obesity, whose effects may in part be mediated by a unique effect on reward pathways, resulting in sustained appetite reduction and enhanced control of eating behavior. 43 The individual components of NB have been used independently for decades to treat a variety of disorders. Naltrexone is an opioid antagonist that has been used clinically in the treatment of opioid and alcohol dependence. 44 Bupropion is a dopamine and norepinephrine re-uptake inhibitor that has been used to treat nicotine dependence, depression, and seasonal affective disorder. 45 Bupropion has been investigated as monotherapy for weight loss, its effect is believed to be due in part to a combined dopaminergic and noradrenergic effect on POMC signaling. 46 As expected as a single drug therapy it is been associated with modest weight loss in clinical studies. [47] [48] [49] The limited efficacy of bupropion monotherapy was in part explained with the novel finding that POMC stimulation also initiates an opioid-mediated auto-inhibition pathway. 17 It was this novel finding that led to the concept of adding naltrexone, a m-opioid receptor antagonist, which therefore slows down this auto-inhibition mechanism. By combining naltrexone with bupropion it would be possible to sustain POMC activation, leading to more weight loss than with bupropion alone. 50 Selective antagonism of the m-opioid receptor has also been associated with reducing the motivational properties of stimuli that elicit the binge eating commonly associated with obesity. 51 Animal studies have shown that naltrexone influences neural reward pathways and hedonic eating behavior. 52 Because naltrexone does not have a direct and independent effect on hypothalamic control of energy balance (i.e., naltrexone attenuates autoinhibition in response to increased POMC activity), naltrexone by itself has failed to produce consistent or clinically meaningful weight loss when administered as monotherapy. 53, 54 It is believed that in addition to stimulation of POMC neurons, the NB combination regulates the mesolimbic dopaminergic reward pathways, which may lead to further weight reduction by modulating reward values and goal-oriented behaviors. 50, 55 Preclinical studies have shown that direct administration of naltrexone and bupropion into the reward system results in a synergistic reduction in food intake, 56 suggesting that the two drugs have complementary actions in the reward system.
Clinical Studies-Effect on Weight Loss and Cardiometabolic Risk Factors
An important phase II dose-ranging study that led to phase III dose selection demonstrated that the NB combination was synergistic and more effective than the individual components. 57 In this study of the NB and -1.1 % for placebo. At week 24, the weight loss of the combination was greater than the sum of the weight loss resulting from the individual components as monotherapy. The trajectory of weight loss was also sustained to week 48, in contrast to the plateau at week 24 observed with monotherapies (see Figure 2 ). participants and comprised four studies, which are summarized in Table 1 and Figure 3 . [58] [59] [60] [61] These studies demonstrated that weight loss with NB was seen as early as week 4 and was sustained for at least 56
weeks. In COR-I, bupropion sustained-release (360 mg/day) combined with naltrexone sustained-release 32 mg/day (NB 32) or 16 mg/day (NB 16) were compared with placebo. 58 The mean change in body weight 63 These improvements were observed as early as week 8.
58-60
Clinical Studies-Effect on Eating Behavior
In addition to measures of weight loss, and cardiovascular and metabolic risk each of the COR studies had secondary endpoints of assessment of eating behavior through use of the Control of Eating Questionnaire (CoEQ), a behavioral measure instrument. 64 An analysis of all COR studies showed that NB was associated with a significant improvement in a number of CoEQ items related to control of eating and cravings (see Figure 4) . 30 Specifically, there was a significant improvement relative to placebo in response to the following questions:
• How hungry have you felt?
• During the last 7 days how often have you had food cravings?
• How strong have any food cravings been?
• How difficult has it been to resist any food cravings?
• Generally, how difficult has it been to control your eating?
In addition, there was a correlation between ability to control eating and weight loss. Individuals who reported greater ability to control their eating at week 8 had greater weight loss at week 56. 30 In a separate study of 40 obese women, functional magnetic resonance imaging (fMRI) demonstrated that NB 32 decreased hypothalamic reactivity to food cues while enhancing the activation of regions involved in self-control and internal awareness. How strong was your desire to eat sweet foods? How strong was your desire to eat tasty foods that are not sweet? 30 
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Clinical Studies-Safety and Tolerability
The most common (≥10 %) treatment-emergent adverse events associated with NB were: nausea (32 % NB versus 7 % placebo), constipation (19 % NB versus 7 % placebo), headache (18 % NB versus 10 % placebo), and vomiting (11 % NB versus 3 % placebo). 66 These were primarily mild to moderate in severity, occurred early in the treatment course, and did not lead to treatment discontinuation in the majority of patients. [58] [59] [60] [61] Nausea led to treatment discontinuation in 6.3 %, 6.0 %, 4.6 %, and 9.6 % in COR-I, COR-II, COR-BMOD, and COR-DM, respectively. The incidence of subjects with serious adverse events was low (≤1.6 %) in all trials (the highest rates reported were 3.9 % for NB and 4.7 % for placebo in COR-DM). 61 Bupropion is an antidepressant and has been associated with rare occurrences of psychiatric symptoms during treatment and after drug cessation. 67 The Importantly, overall weight loss was primarily (78 %) the result of loss of adipose tissue, which is similar to the pattern of weight loss observed with diet and exercise.
Summary and Concluding Remarks
The unmet need of pharmacologic treatment of obesity is slowly changing and physicians will have multiple new pharmacologic treatment options. The timing of this could not be better in the face of our current obesity pandemic and its consequences on health and health care
budgets. Obesity has many causes and one well-studied aspect is food overconsumption driven by sensitivity to food stimuli and the pleasure derived from eating. These processes should be effective targets for pharmacotherapy.
NB represents a novel approach that may influence both the hypothalamic control of energy balance and the mesolimbic reward system. This dual mechanism of action will have its place in treatment of the obese patient. Of interest is that this medication may have advantages in patients struggling with craving and overconsumption related to using food as reward.
The weight loss achieved with NB is significant and sustained with an acceptable safety and tolerability profile. Clinical studies have demonstrated that the drug will yield optimal results when combined with lifestyle modifications involving decreased food intake together with increased physical activity. NB therefore represents a new and welcomed pharmacologic option for patients and physicians. n
